A prospective observational study to explore the efficacy of oral zinc supplementation in patients with anticancer drug-associated skin disorders.

A prospective observational study to explore the efficacy of oral zinc supplementation in patients with anticancer drug-associated skin disorders. - A prospective observational study to explore the efficacy of oral zinc supplementation in patients with anticancer drug-associated skin disorders.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061357

Enrollment

Registered

2026-04-22

Start date

2026-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with solid tumors aged 20 years or older 2. Individuals scheduled to newly initiate EGFR-TKI, VEGFR-TKI, immune checkpoint inhibitor, anti-Nectin-4 antibody microtubule inhibitor conjugate (enfortumab vedotin), or androgen receptor inhibitor (apalutamide) at Fukui University Hospital between February 1, 2026 and December 31, 2027 [Fukui University 1.1] 3. Individuals with hypozincemia 4. Individuals with Grade 0 skin disorders at the time of registration 5. Individuals who can take the medication orally 6. Individuals who understand the research objectives and provide written consent.

Exclusion criteria

Exclusion criteria: 1. Individuals with pre-existing skin disorders 2. Individuals with zinc allergies or those who have previously experienced adverse reactions to zinc preparations 3. Individuals for whom zinc supplementation is deemed unsuitable, such as those with peptic ulcers 4. Individuals with hyperzincemia at the time of initial measurement 5. Pregnant or breastfeeding women, or those planning to become pregnant 6. Individuals whose attending physician deems participation in this study inappropriate

Design outcomes

Primary

Measure	Time frame
Incidence of drug-induced skin disorders	—

Secondary

Measure	Time frame
DLQI, PRO-CTCAE	—

Countries

Japan

Contacts

Public ContactYoshinaga Okumura

University of Fukui Department of Urology

urokumura@gmail.com0776618174

Outcome results